KDR and neoplasm: Anlotinib is an oral novel multitargeted TKI that inhibits angiogenesis and tumor cell proliferation by targeting VEGFR, platelet‐derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFRs), tyrosine kinase (c‐Kit).7